Axova Research BPC-157 (Body Protection Compound-157) is a high-purity synthetic pentadecapeptide representing a partial sequence of the naturally occurring human gastric juice protein. In biological and soft-tissue injury models, BPC-157 is heavily investigated for its distinct cytoprotective (cell-protecting) traits and its ability to accelerate the healing cascades of complex, poorly vascularized tissues.
Unlike traditional growth factors, BPC-157 is highly stable and does not require complex carrier proteins. Researchers frequently utilize this peptide to study the upregulation of growth hormone receptors, the modulation of early angiogenic (new blood vessel) pathways, and the optimization of collagen synthesis required to repair tendons, ligaments, and mucosal linings.
Investigative Highlights:
- Angiogenesis Modulation: Researching the formation of new capillary networks to bypass damaged areas and accelerate localized recovery.
- Soft Tissue Repair Dynamics: Investigating collagen alignment and fibroblast migration in tendon-to-bone healing models.
- Cytoprotective Properties: Studying the stabilization of cellular membranes against systemic inflammatory or chemical stress.
Technical Specifications:
- Chemical Profile: Body Protection Compound-157 (Pentadecapeptide)
- Molecular Formula: C62H98N16O22
- Molecular Weight: 1419.53 g/mol
- CAS Number: 137525-51-0
- Sequence: H-Gly-Glu-Pro-Pro-Pro-Gln-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val-OH
- Purity: 99%+ (Verified by HPLC/MS)
- Physical State: Lyophilized white powder
Storage & Handling:
- Storage: Store desiccated at -20°C for optimal long-term stability. Post-reconstitution, store refrigerated at 2-8°C.
- Reconstitution: For precise analytical measurements and maximum peptide integrity, utilize Axova Research Bacteriostatic Water.
Shipping & Logistics:
-
Orders are processed and dispatched within 1 business day.
Research Disclaimer:
-
This product is strictly for Laboratory Research Use Only. Not for human or veterinary administration.





Reviews
There are no reviews yet.